News - Anti-Arthritics/Rheumatics, Research

Filter

Popular Filters

1 to 25 of 92 results

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

12-06-2014

USA-based privately-held Epirus Biopharmaceuticals, focused on the development and commercialization…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBOW015EPIRUS BiopharmaceuticalsinfliximabRemicadeResearch

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

12-06-2014

French drug major Sanofi and partner US biotech firm Regeneron Pharmaceuticals have presented positive…

Anti-Arthritics/RheumaticsBiotechnologyRegeneronResearchSanofisarilumab

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

12-06-2014

Belgium’s leading drugmaker UCB today presented new long-term data on Cimzia (certolizumab pegol) in…

Anti-Arthritics/RheumaticsBiotechnologyCimziaResearchUCB

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

Timing of AstraZeneca’s positive pipeline announcement “pertinent” in wake of takeover battle with Pfizer, say GlobalData analysts

21-05-2014

Anglo-Swedish drug major AstraZeneca may have more ammunition to deliver on promises made to investors…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyImmunologicalsMavrilimumabMedImmuneResearchSifalimumab

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

NIH in $235 million partnership for lupus and other complex disease treatments

NIH in $235 million partnership for lupus and other complex disease treatments

05-02-2014

In the USA, the Lupus Foundation of America says that it will partner with the Foundation for the National…

Anti-Arthritics/RheumaticsFinancialPharmaceuticalResearch

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

CleveXel Pharma and Dynamix to develop oral treatment for RA

25-11-2013

CleveXel Pharma has entered into a partnering agreement with venture-backed Israeli biopharmaceutical…

Anti-Arthritics/RheumaticsCleveXel PharmaDynamix PharmaceuticalsEuropeLicensingPharmaceuticalResearchRest of the World

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

Sanofi and Regeneron report positive Phase III results with sarilumab in RA

22-11-2013

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have…

Anti-Arthritics/RheumaticsEuropeNorth AmericaPharmaceuticalRegeneronResearchSanofisarilumabUSA

Merck Serono collaborates with Biopharm GmbH on osteoarthritis research

Merck Serono collaborates with Biopharm GmbH on osteoarthritis research

20-11-2013

Privately-held Biopharma GmbH says it has signed an agreement with Merck Serono, the biopharma subsidiary…

Anti-Arthritics/RheumaticsBiopharm GmbHMerck KGaAMerck SeronoPharmaceuticalResearch

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

29-10-2013

US drug major Bristol-Myers Squibb and partner privately-held Alder Biopharmaceuticals have presented…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBristol-Myers SquibbclazakizumabnivolumabOncologyPharmaceuticalResearch

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

1 to 25 of 92 results

Back to top